Source comparison
Comparison at a glance
MK-677 (ibutamoren) Ghrelin-receptor agonist; raises GH/IGF-1; increased fat-free mass in a 2-year RCT Moderate (human RCT) No gain in strength or function; raised fasting glucose, lowered insulin sensitivity Sermorelin GHRH analog; raises IGF-1; small lean-ma
This comparison does not assign a generated winner or score.
- MK-677 (ibutamoren)
- Ghrelin-receptor agonist; raises GH/IGF-1; increased fat-free mass in a 2-year RCT
- Moderate (human RCT)
- No gain in strength or function; raised fasting glucose, lowered insulin sensitivity
- Sermorelin
- GHRH analog; raises IGF-1; small lean-mass rise (men only) in a related-analog trial
- Weak human
- Tiny studies; no effect in women; muscle outcome minimal
- CJC-1295
- Long-acting GHRH analog; sustained rise in GH/IGF-1 in healthy adults
- Indirect only
- Human trial measured hormones, not muscle mass or strength
- Ipamorelin
- Selective GH secretagogue (MK-677-like mechanism)
- Preclinical / none
- No human muscle-growth trial; human use studied mainly for gut motility
- IGF-1 LR3
- Long-acting IGF-1 analog; muscle hypertrophy in animal overexpression models
- Animal / preclinical
- No human trials; systemic IGF-1 signaling carries theoretical risk
- Follistatin-344
- Myostatin antagonist; large muscle gains in animals
- Preclinical peptide; human data only via gene therapy
- Human benefit shown only with AAV gene therapy in disease, not the injectable peptide